Positive and negative regulation by NK cells in cancer

Critical Reviews in Oncogenesis

Volumn 19, Issue 1-2, 2014, Pages 57-66

  Sungur, Can M ^a   Murphy, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer immunoevasion; Cancer immunology; Natural killer cells

Indexed keywords

ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SUPPRESSOR CELL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84899627559     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2014010805     Document Type: Article

References (77)

1. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003;90:127-156.
2. Moretta L, Bottino C, Pende D, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: their origin, receptors and function. Eur J Immunol. 2002 May;32(5):1205-1211.
3. Cudkowicz G, Bennett M. Peculiar immu-nobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice. J Exper Med. 1971 Jul 1;134(1):83-102.
4. Cudkowicz G, Bennett M. Peculiar immunobi-ology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exper Med. 1971 Dec 1;134(6):1513-1528.
5. Bennett M. Prevention of marrow allograft rejection with radioactive strontium: evidence for marrow-dependent efector cells. J Immunol. 1973 Feb;110(2):510-516.
6. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of efector cells. Int J Cancer. 1975 Aug 15;16(2):230-239.
7. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lym-phoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specifcity. International Journal of Cancer Journal International du Cancer. 1975 Aug 15;16(2):216-229.
8. Kiessling R, Klein E, Pross H, Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specifcity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol. 1975 Feb;5(2):117-121.
9. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specifcity for mouse Moloney leukemia cells. Specifcity and distribution according to genotype. Eur J Immunol. 1975 Feb;5(2):112-117.
10. Welsh RM Jr. Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice. I. Characterization of natural killer cell induction. J Exper Med. 1978 Jul 1;148(1):163-181.
11. Jondal M, Spine C, Targan S. Human spontaneous killer cells selective for tumour-derived target cells. Nature. 1978 Mar 2;272(5648):62-64.
12. Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N'Guyen T, Tieblemont N, Delneste Y. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood. 2004 Sep 15;104(6):1778-1783.
13. Bouzani M, Ok M, McCormick A, Ebel F, Kurzai O, Morton CO, Einsele H, Loefer J. Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. J Immunol. 2011 Aug 1;187(3):1369-1376.
14. Li SS, Kyei SK, Timm-McCann M, Ogbomo H, Jones GJ, Shi M, Xiang RF, Oykhman P, Huston SM, Islam A, Gill MJ, Robbins SM, Mody CH. Te NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK Cells from HIV-infected patients. Cell Host Microbe. 2013 Oct 16;14(4):387-397.
15. Sun K, Alvarez M, Ames E, Barao I, Chen M, Longo DL, Redelman D, Murphy WJ. Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood. 2012 Feb 9;119(6):1590-1598.
16. Murphy WJ, Bennett M, Kumar V, Longo DL. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol. 1992 May 1;148(9):2953-2960.
17. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature. 2012 Jan 19;481(7381):394-398.
18. Kumar P, Takar MS, Ouyang W, Malarkannan S. IL-22 from conventional NK cells is epithelial regenerative and infammation protective during infuenza infection. Mucosal Immunology. 2013 Jan;6(1):69-82.
19. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003 Apr 15;101(8):3052-3057.
20. Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood. 1996 Sep 15;88(6):2279-2287.
21. Martin-Fontecha A, Tomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nature Immunol. 2004 Dec;5(12):1260-1265.
22. Lanier LL. Activating and inhibitory NK cell receptors. Adv Exper Med Biol. 1998;452:13-18.
23. Lanier LL. NK cell receptors. Ann Rev Immunol. 1998;16:359-393.
24. Leong JW, Fehniger TA. Human NK cells: SET to kill. Blood. 2011 Feb 24;117(8):2297-2298.
25. Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, purifcation, and functional assessment of human peripheral blood NK cells. J Visual Exper. 2011 Feb 2;(48).
26. Hebert P, Pruett SB. Selective loss of viability of mouse NK cells in culture is associated with decreased NK cell lytic function. In Vitro Molec Toxicol. 2001 Summer;14(2):71-82.
27. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity. 2007 Jun;26(6):798-811.
28. Parham P. Te genetic and evolutionary balances in human NK cell receptor diversity. Sem Immunol. 2008 Dec;20(6):311-316.
29. Murphy WJ. Of mice and men. Biol Blood Marrow Transplant. 2013 Aug;19(8):1140-1141.
30. Jewett A, Wang MY, Teruel A, Poupak Z, Bostanian Z, Park NH. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: efect on the function of natural killer cells. Human Immunology. 2003 May;64(5):505-520.
31. Lutz CT, Kurago ZB. Human leukocyte antigen class I expression on squamous cell carcin-oma cells regulates natural killer cell activity. Cancer Res. 1999 Nov 15;59(22):5793-5799.
32. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011 Jul;11(7):802-807.
33. Cofelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: efectors of angiogen-esis and tumor progression. Biochim Biophys Acta. 2009 Aug;1796(1):11-18.
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-674.
35. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunological Reviews. 2006 Dec;214:47-55.
36. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specifc for self-MHC molecules. Blood. 2005 Jun 1;105(11):4416-4423.
37. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005 Aug 4;436(7051):709-713.
38. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagné F, Ugolini S, Vivier E. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006 Aug;25(2):331-342.
39. Sungur CM, Tang-Feldman YJ, Zamora AE, Alvarez M, Pomeroy C, Murphy WJ. Murine NK-cell licensing is refective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. Blood. 2013 Aug 22;122(8):1518-1521.
40. Sungur CM, Tang-Feldman YJ, Ames E, Alvarez M, Chen M, Longo DL, Pomeroy C, Murphy WJ. Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. Proc Nat Acad Sci USA. 2013 Apr 30;110(18):7401-7406.
41. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Pual P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Romer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Gutierrez JC, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, vivier E, Lecesne A, Kroemer G, Zitvogel L. Alternatively spliced NKp30 isoforms afect the prognosis of gastrointestinal stromal tumors. Nature Med. 2011 Jun;17(6):700-707.
42. Della Chiesa M, Falco M, Podesta M, Locatelli F, Moretta L, Frassoni F, Moretta A. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood. 2012 Jan 12;119(2):399-410.
43. Gasteiger G, Hemmers S, Bos PD, Sun JC, Rudensky AY. IL-2-dependent adaptive control of NK cell homeostasis. J Exper Med. 2013 Jun 3;210(6):1179-1187.
44. Gasteiger G, Hemmers S, Firth MA, Le Floc'h A, Huse M, Sun JC, Rudensky AY. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exper Med. 2013 Jun 3;210(6):1167-1178.
45. Yuan D, Koh CY, Wilder JA. Interactions between B lymphocytes and NK cells. FASEB. 1994 Oct;8(13):1012-1018.
46. Blanca IR, Bere EW, Young HA, Ortaldo JR. Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: role of memory B cells and CD5+ B cells. J Immunol. 2001 Dec 1;167(11):6132-6139.
47. Chung AW, Navis M, Isitman G, Centre R, Finlayson R, Bloch M, Gelgor L, Kelleher A, Kent SJ, Stratov I. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol. 2011 Apr;24(2):171-175.
48. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends Immunol. 2004 Jan;25(1):47-52.
49. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol. 2004 Feb 1;172(3):1333-1339.
50. Simhadri VL, Hansen HP, Simhadri VR, Reiners KS, Bessler M, Engert A, von Strandmann EP. A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells. Biol Chem. 2012 Jan 1;393(1-2):101-106.
51. Spaggiari GM, Carosio R, Pende D, Marcenaro S, Rivera P, Zocchi MR, Moretta L, Poggi A. NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur J Immunol. 2001 Jun;31(6):1656-1665.
52. Stadnisky MD, Xie X, Coats ER, Bullock TN, Brown MG. Self MHC class I-licensed NK cells enhance adaptive CD8 T-cell viral immunity. Blood. 2011 May 12;117(19):5133-5141.
53. Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 liga-tion. Cancer Res. 2007 Nov 1;67(21):10528-10537.
54. Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD Jr, Tate K, Ritchie DS, Negrin RS. Rapid development of exhaustion and down-regulation of eomesoder-min limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012 Jun 14;119(24):5758-5768.
55. McDermott DF, Regan MM, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. Clin Genitourinary Cancer. 2006 Sep;5(2):114-119.
56. Yao H, Ng SS, Huo LF, Chow BK, Shen Z, Yang M, Sze J, Ko O, Li M, Yue A, Lu LW, Bian XW, Kung HF, Lin MC. Efective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle. Molec Cancer Ter. 2011 Jun;10(6):1082-1092.
57. Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE, Shapiro CL. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treatment. 2009 Sep;117(1):83-89.
58. Queluz T T, Brunda M, Vladutiu AO, Brentjens JR, Andres G. Morphological basis of pulmonary edema in mice with cytokine-induced vascular leak syndrome. Exper Lung Res. 1991 Nov-Dec;17(6):1095-1108.
59. Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, Jacob HS. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleu-kin-2. Trans Assoc Amer Phys. 1987;100:21-27.
60. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fuid mediated by the systemic administration of recom-binant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735-1742.
61. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immuno-therapy for cancer. Cytokine Growth Factor Rev. 2002 Apr;13(2):169-183.
62. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immu-notherapy. Cytokine Growth Factor Rev. 2011 Apr;22(2):99-108.
63. Hallett WH, Ames E, Alvarez M, Barao I, Taylor PA, Blazar BR, Murphy WJ. Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transplant. 2008 Oct;14(10):1088-1099.
64. Castillo EF, Stonier SW, Frasca L, Schluns KS. Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. J Immunol. 2009 Oct 15;183(8):4948-4956.
65. Barao I, Alvarez M, Redelman D, Weiss JM, Ortaldo JR, Wiltrout RH, Murphy WJ. Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2011 Dec;17(12):1754-1764.
66. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-1687.
67. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005 Apr 15;105(8):3051-3057.
68. Koh CY, Ortaldo JR, Blazar BR, Bennett M, Murphy WJ. NK-cell purging of leukemia: superior antitumor efects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood. 2003 Dec 1;102(12):4067-4075.
69. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A. Natural killer cell allore-activity in allogeneic hematopoietic transplantation. Curr Opin Oncol. 2007 Mar;19(2):142-147.
70. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen F T. Natural killer cell allorecog-nition of missing self in allogeneic hemato-poietic transplantation: a tool for immuno-therapy of leukemia. Curr Opin Immunol. 2009 Oct;21(5):525-530.
71. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ, Hsu KC. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit efector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood. 2009 Apr 16;113(16):3875-3884.
72. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Efectiveness of donor natural killer cell allore-activity in mismatched hematopoietic transplants. Science. 2002 Mar 15;295(5562): 2097-2100.
73. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identifcation of human brain tumour initiating cells. Nature. 2004 Nov 18;432(7015):396-401.
74. Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol. 2012 Mar;22(2):159-174.
75. Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN, La Rocca R, Mandelboim O, Stassi G, Di Fabrizio E, Parmiani G, Moretta A, Dieli F, Kärre K, Carbone E. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol. 2013 Mar 1;190(5):2381-2390.
76. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor efects by the proteasome inhibitor bortezomib. PNAS USA. 2004 May 25;101(21):8120-8125.
77. Ames E, Hallett WH, Murphy WJ. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exper Immunol. 2009 Mar;155(3):504-513.